Core Viewpoint - CRISPR Therapeutics AG plans to offer $350 million in convertible senior notes due 2031, with an option for an additional $52.5 million, to qualified institutional buyers, subject to market conditions [1][2] Group 1: Offering Details - The notes will be senior, unsecured obligations of the company, accruing interest payable semiannually starting September 1, 2026, and maturing on March 1, 2031 [2] - Upon conversion, the company will deliver common shares with a nominal value of CHF 0.03 per share, with specific terms to be determined at the pricing of the offering [2] Group 2: Use of Proceeds - The net proceeds from the offering are intended for general corporate purposes [3] Group 3: Company Overview - CRISPR Therapeutics is a leading biopharmaceutical company focused on developing gene-based medicines for serious diseases, having achieved a milestone with the approval of CASGEVY, the first CRISPR-based therapy for sickle cell disease and beta thalassemia [5] - The company has a diversified pipeline across various therapeutic areas, including hemoglobinopathies, cardiovascular, autoimmune, oncology, regenerative medicine, and rare diseases [5] - CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals, and operates R&D facilities in Boston and San Francisco [5]